Background {#Sec1}
==========

Niemann-Pick disease type C (NP-C) is a rare neurovisceral lipid storage disorder characterised by progressive, disabling neurological symptoms and premature death in most patients \[[@CR1]--[@CR3]\]. It is caused by autosomal recessive inheritance of mutations in either of two genes (*NPC1* and *NPC2*), and has been estimated to affect one case in every 100,000--120,000 live births \[[@CR1], [@CR2], [@CR4]\].

The clinical presentation of NP-C is highly heterogeneous, necessitating a multidisciplinary diagnostic process that takes into account clinical assessments, histological and electron microscopic tests, and biochemical and molecular genetic laboratory studies \[[@CR1], [@CR5]\]. Clinical work-up requires detection and recognition of numerous non-specific systemic and neurological signs and symptoms. While ancillary testing helps to narrow the differential diagnosis, final confirmation of NP-C requires demonstration of characteristic intralysosomal accumulation of unesterified cholesterol (based on filipin staining in cultured skin fibroblasts) and/or the identification of one or more disease-causing mutations in either the *NPC1* or *NPC2* genes \[[@CR1], [@CR2]\]. The demonstration of abnormal cholesterol homeostasis with impaired low-density lipoprotein (LDL)-induced cholesterol esterification can also provide supportive data in cases with an uncertain biochemical phenotype, but is rarely performed now \[[@CR5], [@CR6]\]. Newer screening and diagnostic tools have recently been developed. The NP-C suspicion index (SI) allows more rapid detection of patients who warrant further testing for NP-C \[[@CR7]--[@CR9]\]. Laboratory measurements of plasma oxysterols (particularly cholestane-3β,5α,6β-triol and 7-ketocholesterol) \[[@CR10]--[@CR12]\], and certain sphingolipids such as lyso-sphingosine \[[@CR13], [@CR14]\], have shown promise in allowing more rapid diagnosis in patients with suggestive clinical signs and symptoms. The increasing application of these newer measures is expected to increase the efficiency of diagnosis in NP-C.

Previous studies in cohorts of NP-C patients from France, Spain, Portugal and the USA have accrued data describing the biochemical and clinical phenotypes, genetics and natural history of NP-C \[[@CR15]--[@CR17]\]. NP-C has historically been considered a childhood-onset disease, but patients with late-onset symptoms are increasingly being detected due to the wider application of biochemical and genetic diagnostic techniques. In 2007, a retrospective case note review documented clinical signs and symptoms and subsequent disease course based on 94 NP-C patients diagnosed in the UK between 1999 and 2006 \[[@CR15]\]. Data were available from approximately even numbers of patients with neonatal-onset (*n* = 33), childhood-onset (*n* = 31) and adolescent/adult-onset disease (*n* = 30), and a detection rate of 4--5 new cases per year between 1990 and 1999 was reported \[[@CR15]\].

Major efforts have been made in the last decade to further consolidate clinical data from all known NP-C patients diagnosed and managed in the UK. This report provides an update of information from the UK NP-C database based on data collected between 1999 and the end of 2011, including a further 52 patients since the previous report in 2006 \[[@CR15]\].

Methods {#Sec2}
=======

The UK NP-C database {#Sec3}
--------------------

We reviewed retrospective data for all UK-based patients with NP-C whose details were stored in a database maintained by the Niemann-Pick Disease Clinical Nurse Specialist at the Department of Genetic Medicine, University of Manchester, UK. All data were collected during clinical visits forming part of ongoing long-term care. The database contained information from all UK patients with a diagnosis of NP-C that had been confirmed using filipin staining, causal gene mutation analysis and/or esterification studies between 1999 and the end of 2011 (data cut-off). All patients were either referred or self-referred to the Nurse Specialist or Support Group.

Diagnostic information {#Sec4}
----------------------

Laboratory diagnostic data for all patients are included from at least one of three laboratories in the UK and/or France that provide the required specialised testing. Diagnostic Laboratories in the UK and Lyon, France were involved independently in submitting information on cases they diagnosed to the database.

In general diagnostic information included findings from skin biopsy analyses (filipin staining and cholesterol esterification assays) from all UK patients with: 1) clinical symptoms suggestive of NP-C and; 2) raised plasma chitotriosidase (routinely checked alongside white-cell enzymes if laboratory analyses hinted at a possible lysosomal storage disease). *NPC1* gene sequencing analyses were conducted in all patients with positive filipin staining and/or cholesterol esterification findings, and some sibling cases. Patients in whom *NPC1* mutations were not identified, or on whom complementation studies have not been performed, underwent further investigations and *NPC2* gene sequencing.

Clinical manifestations {#Sec5}
-----------------------

During the observation period, information on key signs and symptoms of NP-C were recorded up to the last clinical follow up (i.e., last clinic visit and/or update of medical records in the database) in line with international guidelines for the diagnostic assessment and follow-up of the disease \[[@CR1]\]. The following data types were included whenever possible: oculomotor signs (e.g. vertical supranuclear gaze palsy \[VSGP\]), neurological manifestations (e.g., cerebellar signs \[ataxia, dysarthria, dysphagia, dyskinesia\], seizures/cataplexy); spasticity; childhood developmental status (e.g. psychomotor delay and/or regression, learning disabilities); cognitive loss/problems, psychiatric abnormalities (e.g., psychosis, behavioural abnormalities); and systemic symptoms (e.g., hepatosplenomegaly, lung disease or neonatal cholestatic disease). Information on miglustat therapy was also included, where available, for all treated patients.

Ethical data reporting {#Sec6}
----------------------

All information was accessed in accordance with applicable laws and ethical requirements for the study period concerned, and all study procedures, including informed consent for molecular genetic analyses, were conducted in line with ethical standards of the responsible institutional ethics committees and the Helsinki Declaration (1975) and subsequent revisions. All patients and/or their kin provided written informed consent for publication of individual clinical details, as presented in this report. Data reported previously for patients included in this cohort, based on publications by Lachmann et al. \[[@CR18]\], Patterson et al. \[[@CR19]\], and Patterson et al. \[[@CR20]\], are identified where relevant.

Data analysis {#Sec7}
-------------

In recognition of international guidelines for the management of NP-C, patients are assessed based on neonatal presentation of NP-C (characterised mainly by systemic symptoms \[splenomegaly, hepatomegaly, neonatal cholestatic disease and liver failure\], and hereafter referred to as the 'neonatal' form), and as per accepted age subgroups based on onset of neurological manifestations (i.e., early infantile- \[\<2 years\], late infantile- \[2 to \<6 years\], juvenile- \[6--15 years\] and adolescent/adult-onset \[\>15 years\]). Patients with a confirmed diagnosis but, as yet, no neurological symptoms, were also included in a 'non neurological' category.

All data analyses were exploratory in nature, and no statistical analyses of differences between patient subgroups were performed. Data are presented using descriptive statistics (mean, SD, median and range for continuous variables, and n (%) for categorical values). Patients for whom no numerical data values were available were treated as having 'missing values'.

Results {#Sec8}
=======

Overall cohort characteristics {#Sec9}
------------------------------

This UK cohort comprised a total of 146 NP-C patients born between 1954 and 2009, among whom 77 (53 %) were female and 69 (47 %) male. Patient demographics and general characteristics per patient subgroup are summarised in Table [1](#Tab1){ref-type="table"}. Among a total of 112 patients (77 %) who possessed at least one identified, disease-causing NP-C gene mutation, 110 (98 %) had *NPC1* mutations and two (2 %) had *NPC2* mutations. In patients where genetic analyses did not reveal any known or identifiable novel mutations, diagnoses were based on filipin staining and ancillary methods combined with clinical examination findings and medical history.Table 1Patient demographics and general characteristics per age-at-onset subgroupNeonatal onset (*N* = 6)Early infantile onset (*N* = 8)Late-infantile onset (*N* = 51)Juvenile onset (*N* = 42)Adolescent/adult onset (*N* = 25)Gender, n (%) female3 (50)7 (88)28 (55)25 (60)10 (40)Age, years:At neurological onset n^a^--8504018 Mean (SD)--1.1 (0.7)4.1 (1.2)9.4 (2.6)24.2 (8.8)At diagnosis n^a^4^c^7^c^493924 Mean (SD)0.1 (0.1)1.3 (1.5)4.6 (5.5)11.5 (7.4)29.3 (9.3)At last follow up^b^ n^a^----192117 Mean (SD)----11.6 (8.9)20.2 (9.0)39.5 (9.2)At death n^a^6830198 Mean (SD)0.19 (0.22)5.6 (2.0)13.4 (6.7)25.9 (8.9)33.7 (6.2)Number (%)^d^ with NP-C genetic information1 (17)8 (100)41 (80)36 (86)16 (64)Number (%)^d^ treated with miglustat--2 (25)17 (33)20 (48)12 (48)^a^Number of patients with available data; ^b^last follow up (data cut-off at end-2011) in living patients only; ^c^age at diagnosis not relevant for two neonatal patients and one early-infantile patient who were diagnosed post-mortem; ^d^percentages calculated relative to total number of patients per treatment subgroup

Six patients (4 %) had the visceral neonatal form of NP-C. The numbers (%) of patients per accepted age-at-neurological onset category were: early-infantile onset (*n* = 8 \[5 %\]), late-infantile onset (*n* = 51 \[*n* = 35 %\]), juvenile onset (*n* = 42 \[29 %\]); and adolescent/adult onset (*n* = 25 \[17 %\]). A total of 14 patients (10 %), most of whom were detected due to early visceral symptoms and three of whom had a sibling history of NP-C, had no neurological symptoms and are categorised herein as having non-neurological disease.

The overall mean (SD; range) ages at neurological onset and diagnosis were 8.8 (8.1; 0--40) years and 10.4 (11.5; 0--49.5) years, respectively. In general, age at diagnosis tended to increase in line with age at onset of neurological manifestations (Table [1](#Tab1){ref-type="table"}): NP-C was diagnosed most quickly among patients with infantile onset, with the greatest delays to diagnosis recorded among patients with adolescent/adult onset. A total of 43 patients (29 %) were siblings who were also affected by NP-C. Based on all patients with available data, the mean time period between neurological disease onset and diagnosis was 1.73 (5.80) years, while this period among the sibling subgroup was 1.25 (4.75) years. In many cases, confirmation of a diagnosis of NP-C in one sibling led to a more rapid diagnosis in either younger or older siblings.

Overall, 72/146 (49 %) patients were alive at data cut-off. Among patients with available data, the mean age at last follow up (i.e., the latest clinical assessment before data cut-off at the end of 2011) ranged from 11.6 years in the late-infantile onset subgroup to 39.5 years in the adolescent/adult-onset subgroup. Mean ages at death among the age-at-onset subgroups ranged from 0.19 years among neonatal patients to 33.7 years in the adolescent/adult-onset subgroup. In non-neurological NP-C patients , the mean age at last follow-up among 11 living patients was 2.5 years (range 0.5--6.1). The mean age at death among three non-neurological patients who died was 20.8 (15.9) years (range 4.9--36.7).

Neurological and psychiatric manifestations: overall cohort {#Sec10}
-----------------------------------------------------------

The large majority of patients had at least one neurological manifestation commonly associated with NP-C at last follow up. A total of 19 patients (13 %) had no recorded manifestations, five of whom had the neonatal form of the disease.

Figure [1](#Fig1){ref-type="fig"} summarises the prevalence of individual neurological symptoms per age at onset subgroup. Overall, developmental delay (during childhood) and/or cognitive deterioration were recorded in the greatest proportion of patients up to last follow up (in 119/146 patients \[82 %\]). In order of incidence, other common neurological signs were: ataxia (in 110 patients \[76 %\]), VSGP (103 patients \[71 %\]), dysarthria (99 patients \[68 %\]), dysphagia (93 patients \[64 %\]) and seizures/cataplexy (72 patients \[50 %\]).Fig. 1Occurrence of neurological and psychiatric manifestations per patient subgroup *Percentages calculated based on numbers of patients with available data*

Psychiatric disturbances were recorded in a total of 17 (12 %) patients. As could be expected, all cases in whom psychiatric disturbances were recorded were in the juvenile-onset or adolescent/adult-onset subgroups (incidence per subgroup 8/42 patients \[19 %\] and 9/25 patients \[36 %\], respectively).

Visceral symptoms: overall cohort {#Sec11}
---------------------------------

Visceral symptoms of NP-C were recorded most frequently in patients with the neonatal visceral form of NP-C and in the early infantile-onset and non-neurological subgroups, and least frequently among adolescent/adult-onset patients (Fig. [2](#Fig2){ref-type="fig"}). Prolonged neonatal jaundice with or without neonatal liver disease was by far the most common visceral symptom, occurring in all neonatal onset, 6/8 (75 %) early-infantile onset, 29/51 (57 %) late-infantile onset, and 14/42 (33 %) juvenile-onset patients. Only one adolescent/adult-onset patient had a recorded history of neonatal jaundice. Organomegaly (hepatosplenomegaly in most cases) also tended to occur less and less frequently as age at neurological onset increased. All patients in whom no neurological manifestations have yet been recorded had a history of at least one visceral symptom, most commonly prolonged neonatal jaundice (in 5/14 \[36 %\] patients).Fig. 2Occurrence of visceral symptoms per patient subgroup *Percentages calculated based on numbers of patients with available data*

Clinical symptomatology and outcomes in age-at-onset subgroups {#Sec12}
--------------------------------------------------------------

### Neonatal onset patients {#Sec13}

All six patients with the neonatal form of NP-C had liver disease at or soon after birth (mean \[SD\] age 0.19 \[0.22\] years), with organomegaly also apparent in four cases and foetal ascites present in two (Table [2](#Tab2){ref-type="table"}). Hepatosplenomegaly was also recorded in four cases. Patients with the severe neonatal-onset form of NP-C have been reported in other national cohorts to have a short lifespan \[[@CR2], [@CR16]\], and the same was true in this UK cohort. Two cases were stillborn and the other four died within 1--7 months of birth. Liver disease was the most frequently recorded cause of death (three patients), and one patient died due to failure to thrive and chest infection. One patient (patient 1) had a record of developmental delay from birth.Table 2Patients with neonatal NP-CPatient number/GenderSibshipDate of birthAge at diagnosisAge at last FU/death^a^Neonatal LDHS/SSeizures/cataplexyVSGPDev. delayAtaxiaSwallowing problemsPsychiatric disturbanceSlurred speechMiglustat?Age at 1^st^ miglustat startMiglustat durationGenetic mutations1/M--20004 m4 m^a^PJ LDHS----From birth--------No------2/Fa2001PM0^a^FA----------------No------3/Fa2002PM0^a^FA----------------No------4/Mb1985Birth1 m^a^YesYes--------------No----c.3501C \> G(p.Phe1167Leu)/c.3501C \> G(p.Phe1167Leu)5/Mb1985Birth2 m^a^YesYes--------------No----c.3501C \> G(p.Phe1167Leu)/c.3501C \> G(p.Phe1167Leu)6/Fc20092 m7 m^a^YesYes--------------No----c.3020C \> T(p.Pro1007Leu)/c.3020C \> T(p.Pro1007Leu)^a^Patient died; '--', no data/not known; *C* cataplexy, *E* epilepsy, *FA* foetal ascites, *HS/S* hepatosplenomegaly/splenomegaly, *LD* liver disease, *m* months, *PJ* prolonged jaundice, *PM* post mortem, *y* years, *w* weeks

### Early-infantile onset patients {#Sec14}

All but one of the early-infantile onset patients were female (Table [3](#Tab3){ref-type="table"}). The mean (SD; range) age at onset of neurological manifestations in this subgroup was 1.1 (0.7; 0--2.0) years. Overall, the mean (SD) time between onset of neurological manifestations and diagnosis was 0.26 (1.49) years, with diagnostic testing commenced based on recognition of visceral symptoms in four patients.Table 3Patients with early-infantile neurological onsetPatient number/GenderSibshipDate of birthAge at diagnosisAge at last FU (y, m)/death^b^Neonatal LDHS/SSeizures/cataplexyVSGPDev. delayAtaxiaSwallowing problemsPsychiatric disturbanceSlurred speechMiglustat?Age at 1^st^ miglustat startMiglustat durationGenetic mutations7/F--20004 m3y 4 m^b^PJ LDYesC 2y 11 m--\<18 m\<2y13 m--\<2yNo----c.3578_3591 + 9del/c.3578_3591 + 9del8/F--200619 m3y 9 m^b^PJYesNoNoYesYes19 m--YesNo------9/F--20053 m4y 1 m^b^PJ LD, LTxYes----YesYesYes--YesNo----c.1526A \> C(p.Tyr509Ser/?10/F--20036 m4y 5 m^b^PJ LDYesE 3y 5 m\<18 mYesYes3y--No speechNo----c.2801G \> A(p.Arg934Gln)/c.2978del(p.Gly993Glu fsX4)11/Md1990PM7y 8 m^b^NoNoC 2y E 4yYes\<2y\<2y5y--YesNo----c.2819C \> T(p.Ser940Leu/?^a^12/Fe twin199811 m8y 5 m^b^PJYesC 5y E 5y 10 m3yYesNever mobileNo--\<3yYes7y1wc.3107C \> T(p.Thr1036Met/c.3557G \> A(p.Arg 1186His)13/Fe twin199811 m7y 1 m^b^PJYesC 5y E 5y 10 m3yYesNever mobileNo--\<3yYes7y1wc.3107C \> T(p.Thr1036Met/c.3557G \> A(p.Arg 1186His)14/F--19954y 5 m6y 5 m^b^NoNoC 4y E 5y4y1y 5 m4y5y--Yes------c.3503G \> A(p.Cys1168Tyr)/c.3503G \> A(p.Cys1168Tyr)^a^Second mutant allele not found after full genome sequencing; ^b^Patient died; '--', no data/not known; *C* cataplexy, *E* epilepsy, *FA* foetal ascites, *HS/S* hepatosplenomegaly/splenomegaly, *LD* liver disease, *LTx* liver transplant, *m* months, *PJ* prolonged jaundice, *PM* post mortem, *y* years, *w* weeks

The mean (SD) age at death was 5.6 (2.0) years. The most common recorded cause of death (7/8 cases \[88 %\]) was 'NP-C', reflecting a gradual and in some cases rapid deterioration, with eventual loss of all skills and bodily functions with no one apparent causative factor. However, the recorded causes of death could reflect the way death certificates are completed in the UK, where the primary disease is often stated as the causative factor.

A total of 6/8 patients (75 %) exhibited both prolonged neonatal jaundice and hepatosplenomegaly (Fig. [2](#Fig2){ref-type="fig"}). One patient (patient 9) underwent liver transplantation due to severe cholestatic liver disease.

Developmental delay, ataxia and dysarthria were the most commonly recorded neurological symptoms, each occurring in all eight patients (Fig. [1](#Fig1){ref-type="fig"}). Cataplexy/epileptic seizures and swallowing difficulties were each recorded in 6/8 (75 %) patients. Ophthalmic assessments revealed VSGP in 5/8 (63 %) patients.

### Late-infantile onset patients {#Sec15}

The mean (SD; range) age at neurological onset in this subgroup was 4.1 (1.2; 0.4--8.0) years, and the overall mean (SD) time period between neurological onset and diagnosis among patients with available data was 0.56 (5.25) years. Again, diagnostic testing was commenced in approximately half of this patient subgroup after initial recognition of visceral symptoms.

Overall, 30/51 (59 %) patients died before data cut-off at the end of 2011 (mean \[SD\] age at death 13.4 \[6.7\] years). 'NP-C' was listed as the cause of death in 26/30 patients (87 %) with available information. Pneumonia was listed specifically as the cause of death in two cases, but any association with dysphagia or previous food aspiration was not recorded.

Neurological manifestations were more common than visceral symptoms in this subgroup (Table [4](#Tab4){ref-type="table"}). Again, developmental delay was recorded most frequently (in all 51 patients), followed by ataxia (in 45/51 \[88 %\]) and VSGP (in 42/51 \[82 %\]). Dysarthria, dysphagia and seizures/cataplexy were observed in 42/51 (82 %), 36/51 (71 %) and 34/51 (67 %) patients, respectively (Fig. [1](#Fig1){ref-type="fig"}).Table 4Patients with late-infantile neurological onsetPatient number/GenderSibshipDate of birthAge at diagnosisAge at last FU (y, m)/death^b^Neonatal LDHS/SSeizures/cataplexyVSGPDev. delayAtaxiaSwallowing problemsPsychiatric disturbanceSlurred speechMiglustat?Age at 1^st^ miglustat startMiglustat durationGenetic mutations15/Mf20002y5 y 4 m^b^--\<1y 8 mE \<4y 11 m--\<4y 6 m\<4y 6 m\<4y 6 m--\<3yNo----c.3020C \> T(p.Pro1007Leu)/c.3020C \> T(p.Pro1007Leu)16/F--200411 m7y 2 mPJSNo5y5y4yNo--Mild \<4yYes6y1y--17^a^/M--20051y 2 m6y 7 mHS--No\<6y\<5yNoNo--\<6yYes5y1yc.1526A \> C(p.Tyr509Ser)/c.688_693del(p.Ser230_Val231del18/F--20026 m6y 4 m^b^PJSC 3yYes3yYes3y--3yNo----c.2008_2011del(p.Cys670ProfsX17/?^d^19^a^/M--199015y21y 2 m----E 15yYes5yYes------Yes16y5yc.2292G \> A(p.Gly764Ala)/?20/F--19876y13y 6 m^b^No4y--7y5y 5 m7y4y--YesNo----c.2324A \> C(p.Gln775Pro)/c.2956G \> A(p.Gly986Ser)21/Mg20032y 11 m7y^b^PJHSC 4y2y 11 m3y\<4yYes--\<4yNo----c.2464_2465insT(p.Lys822IlefsX48)/c.2201G \> T(p.ser734Ile)22^a^/Fg20054y6y 10 mSlight jaundiceNoNo\<6y\<5y\<6yNo--\<6yYes3y3yc.2464_2465insT(p.Lys822IlefsX48)/c.2201G \> T(p.ser734Ile)23/Fd19973y 9 m12y 9 m^b^NoNoC 6y6y6y 5 m4y 7 m7y--YesYes----c.2819C \> T(P.Ser940Leu)/?24^a^/F--20017y10y 10 mNoNoE 9y C 8y9y\<5y9y6y--\<6yYes8y2yc.3019C \> g(p.Pro1007Ala)/?25^a^/Fc/twin2006At birth5y 6 mPJ LDHSNo4y\<4y\<4yNo--4yYes4y1yc.3020C \> T(p.Pro1007Leu)/c.3020C \> T(p.Pro1007Leu)26^a^/Fc/twin2006At birth5y 6 mPJ LDHSNo4y\<4y\<4yNo--4yYes4y1yc.3020C \> T(p.Pro1007Leu)/c.3020C \> T(p.Pro1007Leu)27/Ff2008At birth3yYesYesNoNo\<3yMildNo--NoYes0.5y2.5yc.3020C \> T(p.Pro1007Leu)/c.3020C \> T(p.Pro1007Leu)28/M--19949 m9y 3 m^b^PJ LDHSC 4y E 7y4y1y\<5y5y--5yNo----c.3182 T \> C(p.Ile1061Thr)/?^d^29/F--19909 m9y 5 m^b^PJ LDNoYes\<6y\<6y6y 5 m------No----c.3182 T \> C(p.Ile1061Thr)/?30/F--19758y28y^b^PJ LDHSE 17y8y13y5yYes--YesNo----c.3182 T \> C(p.Ile1061Thr)/?31/F--20033 m8y 6 mPJ LDAt birthE 8y4y\<4y\<4y\<7y--5yYes----c.3182 T \> C(p.Ile1061Thr)/?^d^32//Mh19892y11y 2 m^b^PJ LDNoE 6y 5 mYes4yYesYes----No----c.3182 T \> C(p.Ile1061Thr)/?33/Mh19881y8y 5 m^b^PJ LDNoC 6y E 6yNo\<5y--8y----No----c.3182 T \> C(p.Ile1061Thr)/?34/F--19904y 9 m14y^b^No4yC 7y E 8y7y6y4y8y--7yNo----c.3182 T \> C(p.Ile1061Thr)/?35/F--19897y16y^b^NoAt birthC 8y E 10y5y4y4y 5 m9y--YesNo----c.3182 T \> C(p.Ile1061Thr)/?36/M--19878 m12y 1 m^b^PJ LDAt birthC 5y 5 m E 7y 8 m5y5y5y9y--YesNo----c.3182 T \> C(p.Ile1061Thr)/?37/M--19914y 3 m9y^b^PJ LDHS 3yC 5y4y4y 6 m2y5y--YesNo----c.3182 T \> C(p.Ile1061Thr)/?38/M----16y22y 11 m^b^PJNoNo16y8y4y17y--YesNo----c.3182 T \> C(p.Ile1061Thr)/?39/M--20018 m10y 6 mPJHSNoYes4y 6 mYesNo--NoYes7y3yc.3182 T \> C(p.Ile1061Thr)/del10bp96240/M--199510 m10y^b^PJ LDSC 4y 9 m4y\>4yYesYes--YesNo----c.3182 T \> C(p.Ile1061Thr)/c.1142G \> A(p.Trp381X)41/F--199612 m11y 9 m^b^NoHS 9 mC 5y 6 m5y5y5y 6 mNo--11yYes7y4yc.3182 T \> C(p.Ile1061Thr)/c.2656G \> C(p.Gly886Arg)42/F--19839y 5 m25y 7 m^b^NoS 9y 6 mE 5yYesYes12yYes--YesNo----c.3182 T \> C(p.Ile1061Thr)/c.3019C \> G(p.Pro1007Ala)43/F--19936y9y 6 m^b^PJ5yC 5y E6y5y5y5y6y--YesNo----c.3182 T \> C(p.Ile1061Thr)/c.3107C \> T(p.Thr1036Met)44^a^/M--20074 m4y 1 mNCYesNoNo\<3y\<3yNo--\<3yYes2y2yc.3182 T \> C(p.Ile1061Thr)/c.3107C \> T(p.Thr1036Met)45^a^/M--19984 m13y 9 mPJYesC 8y5y9yNoNo--NoYes5y8yc.3182 T \> C(p.Ile1061Thr)/c.3175C \> T(p.Arg1059X)46/F--19967y 8 m15y 6 m^b^NoNoC 8y7y 8 m7y 8 m5y8y 5 m--YesNo----c.3182 T \> C(p.Ile1061Thr)/c.3182 T \> C(p.Ile1061Thr)47^a^/M--2006At birth5yPJ LDYesC \<4yNo3yYes\<5y--\<4yYes4y1yc.3182 T \> C(p.Ile1061Thr)/c.3422 T \> G(p.Val1141Gly)48/F--19823y29y 4 mPJHS at birthNo3y3y5y18y--YesYes----c.3182 T \> C(p.Ile1061Thr)/c.3467A \> G(p.Asn1156Ser)49^a^/F--200112 m10y 7 m^b^NoSC 9y4y4y4y7y--6yNo----c.3182 T \> C(p.Ile1061Thr)/c.3591 + 4delA50^a^/M--20041y 11 m7y 5 m^b^No6 mC 4y4y3y 5 m3y4y 5 m--YesYes5y2yc.3259 T \> C(p.Phe1087Leu)/c.2516 T \> G(p.Ile839Arg)51/Fi19848y 6 m27y 5 mNo2yC 5y8y13y5y13y--11yNo----c.3467A \> G(p.Asn1156Ser)/?^d^52/Fi197814y 5 m33y 5 m^b^NoNoE 13y14y5y13y13y--12yNo----c.3467A \> G(p.Asn1156Ser)/?^d^53/Fj19958y 4 m16y 11 mNoNoE 7y 5 m C 8y6y 9 m3y 5 m4y8y 6 m--YesNo----c.3591 + 4delA/?^d^54^a^/M--2006At birth5y 5 mPJ LDYesNoNoYesNoYes--YesNo----c.58G \> T(p.Glu20X)/c.58G \> T(p.Glu20X) \[NPC2\]55/Mk2000--10y 5 m^b^NoNoC 6y5y5y5y5y--YesNo------56/M--20053y 10 m--Yes------4y------4yNo------57/Fl--2y6y^b^NoHS 6 mNo3y2y 5 m2y 5 m5y--NoNo------58/M----9y 5 m15y^b^NoNoC + E 5y6y6y4y10y--YesNo------59/F--19878y17y 6 m^b^No4yC 5y E 10y7y5y6y11y--YesNo------60/Mb19838y16y^b^PJNoE 16yYes8y5y12y--YesNo----c.3501C \> G(p.Phe1167Leu)/c.3501C \> G(p.Phe1167Leu)61/Ml19907y 1 m17y 5 m^b^NoS 2y 6 mC 10y7y 1 m4y 5 m5y 5 m10y--YesNo------62/F--19935y9y 5 m^b^PJHS 5y 5 mC 5yNo18 m4yNo--YesNo------63/Mk1998----------YesYesYesYes--YesNo------64/F--198229y29y 6 mNoNoNo29yYesYes20y--24yNo----c.3022A \> C(p.Asn108His)/c.182 T \> C(p.Ile 1061Thr)65/F--20082y3y 9 mYesHSNoNoYesNoNo--NoNo----\[*NPC2*\]^ca^Patients included in previously reported NPC Registry baseline characteristics study \[[@CR19]\]; ^b^patient died; ^c^mutation found but information not accessible during observation period; ^d^second mutant allele not found after full genome sequencing. '--', no data/not known; *C* cataplexy, *E* epilepsy, *FA* foetal ascites, *HM* hepatomegaly, *HS/S* hepatosplenomegaly/splenomegaly, *LD* liver disease, *LTx* liver transplant, *m* months, *NC* neonatal cholestasis, *PJ* prolonged jaundice, *PM* post mortem, *y* years, *w* weeks

The only two patients in the UK cohort who had *NPC2* mutations were in this age-at-onset subgroup (patients 54 and 65), both of whom displayed neonatal jaundice and hepatosplenomegaly, as was common among other late-infantile onset patients. However, both of these patients displayed relatively few typical neurological manifestations: patient 54 had developmental delay, dysarthria and dysphagia, and only developmental delay was recorded in patient 65.

Overall, hepatosplenomegaly was the most common visceral symptom in this patient subgroup, recorded in 32/51 (63 %) patients. A history of neonatal jaundice was recorded in 29/51 (57 %) (Fig. [2](#Fig2){ref-type="fig"}).

### Juvenile-onset patients {#Sec16}

Among juvenile-onset patients, neurological manifestations were first noted at a mean (SD; range) age of 9.4 (2.6; 5.0--15.0) years. The mean (SD) time between neurological onset and diagnosis was 1.64 (6.09) years. In this subgroup, diagnostic testing was commenced based on the appearance of neurological signs in the majority (approximately three-quarters) of cases.

In total, 19/42 (45 %) patients had died by data cut-off (mean \[SD\] age at death, 25.9 \[8.9\] years) (Table [5](#Tab5){ref-type="table"}). As for late-infantile onset patients, most deaths (11/18 evaluable patients \[61 %\]) in this subgroup were recorded as being due to 'NP-C'. Four of the 18 (22 %) patients with available information died due to respiratory-related complications but again, no associations with dysphagia or previous aspiration were noted.Table 5Patients with juvenile neurological onsetPatient number/GenderSibshipDate of birthAge at diagnosisAge at last FU (y, m)/death^c^Neonatal LDHS/SSeizures/cataplexyVSGPDev. delay/cognitive problemsAtaxiaSwallowing problemsPsychiatric disturbanceSlurred speechMiglustat?Age at 1^st^ miglustat startMiglustat durationGenetic mutations66/F--197024y 5 m41y 2 mNoYesC 24y12y11y24y24y32y24yYes32y--c.1211G \> A(p.Arg404Gln)/?^d^67/F--199510y 1 m16y 3 mNoNoE 10y 3 m10y 1 m8y10y13yNoYesYes12y4yc.1552C \> T(p.Arg518Trp)/c.283 T \> C(p.Ser95Pro)68/F--199610y 6 m15y 1 m----\<10yYes\<10y\<10y\<10yNo\<10yNo----c.2848G \> A(p.Val950Met)/?69/F--199414y17y 10 mNoNoNoYes10yYesYes--6yNo----c.2974G \> T(p.Gly992Trp)/?70/F--198314y21y 11 m^c^NoNoE 12yYes8y11y17yNoYesNo----c.3019C \> G(p.Pro1007Ala)/?71^a^/M--199117y20y 4 m----E 12yYesAt birthYesYesYesYesYes18y2yc.3019C \> G(p.Pro1007Ala)/c.1553G \> A(p.Arg518Gln72/F--19862 m25y 10 mFA LDAt birthE 14y11y11y14y15yNo\<14yNo----c.3176G \> A(p.Arg1059Gln)/?73/M--199614y15y 5 mNoNoNo12y7y7y13yNo12yYes14y1yc.3182 T \> C(p.Ile1061Thr)/?74/M----7y 5 m20y^c^PJHSNo7y6y 5 m7y8yNoYesNo----c.3182 T \> C(p.Ile1061Thr)/?75/F--198610y19y 2 m^c^NoNoC 11y10y7y7y11yNoYesNo----c.3182 T \> C(p.Ile1061Thr)/?76/M--20007y11y 1 m^c^----E 7yYesYesYesYesNoYesNo----c.3182 T \> C(p.Ile1061Thr)/?77^a^/F--19964y 5 m15y 4 mPJHS 4y 5 mE 12y7y7y6yNoNoNoYes7y8yc.3182 T \> C(p.Ile1061Thr)/c.2801G \> A(p.Arg934Gln)78^a^/F--20022 m9y 10 mPJHSC 6yYes6yNoNoNoNoYes7y2yc.3182 T \> C(p.Ile1061Thr)/c.2819C \> T(p.Ser940Leu)79/F--19854y 1 m26y 4 mPJ LDHS 11yC 7y E 17y11y13y13y16yNoNoYes----c.3182 T \> C(p.Ile1061Thr)/c.2974G \> T(p.Gly992Trp)80/Mm197812y18y 8 m^c^NoS 2--10yE 11y10y8y10y18yNoYesNo----c.3182 T \> C(p.Ile1061Thr)/c.3019C \> G(p.Pro1007Ala81/M--20036 m8y 8 mPJ LDHS----No--------Yes7y1yc.3182 T \> C(p.Ile1061Thr)/ c.3182 T \> C(p.Ile1061Thr)82/M--1970At birth32y^c^NoNoE 22yYes12yYes27yNoYesNo----c.3182 T \> C(p.Ile1061Thr)/ c.3182 T \> C(p.Ile1061Thr)83/F--199113y18y 2 m^c^NoNoNoYes10y14y14y 5 mNoYesNo----c.3182 T \> C(p.Ile1061Thr)/ c.3182 T \> C(p.Ile1061Thr)84^b^/M--198812y23y 7 mNoS 7 yNo11y 9 m17y17yNoNoNoYes21y2yc.3182 T \> C(p.Ile1061Thr)/ c.3182 T \> C(p.Ile1061Thr)85^b^/F--19916y 5 m20y 1 mNoS 5y 5 mNo8y 3 m11y 1 m9y19yNoNoYes12y8yc.3182 T \> C(p.Ile1061Thr)/c.3493G \> A(p.Val1165Met)86/F--20058w6y 6 mPJ LDHSNoMild 6yNoNoNoNoNoYes4y2yc.3182 T \> C(p.Ile1061Thr)/c.350-351delAG87/F--198617y25y 5 mNoNoE 16yYes5y (FAS)\<16y\<16y--YesNo----c.3182 T \> C(p.Ile1061Thr)/c.3566A \> G(p.Glu1189Gly)88/M--198518y26y 7 mNoS 18 yNo15y13y13y18y18y 6 m18yYes----c.3182 T \> C(p.Ile1061Thr)/c.3566A \> G(p.Glu1189Gly)89^a^/F--199410y 4 m17y 9 mNoNoC \<4y E \<17y\<17y\<10y 4 m\<10y 4 m\<17yNo\<17yYes14y3yc.3182 T \> C(p.Ile1061Thr)/c.410C \> T(p.Thr137Met)90/F--198315y22y 8 m^c^PJBirthE 14y11y8y11y16yNoYesNo----c.3263A \> G(p.Tyr1088Cys)/c.1201C \> A(p.Pro401Thr)91/M--198917y23yNoNoNoYes8y9y18y17y17yYes18y3 mc.3493A \> G(p.Val1165Met)/c.3493A \> G(p.Val1165Met)92/Fb19903 m17y 2 m^c^PJNoE 15y11y10y10y 5 m15yNoYesYes----c.3501C \> G(p.Phe1167Leu)/c.3501C \> G(p.Phe1167Leu)93/Fj199810y13y 6 mNoNoYesYesYesYesYesNoYesYes10y3yc.3591 + 4delAla/?94/F--199710y14y 8 m^c^NoNoC + E 10yNo\<10y\<10yYes GxNoYesNo----c.3019C \> G(p.Pro1007Ala)/c.2464-2465insT95/M--199812y13y 6 mNoNoC 11y11y9yTremor 11yNoNo\<5yYes13y6 m--96/F--19969y15y 8 m^c^Mild jaundiceS--YesYesYesYes GxNo9yNo------97/F--199116y17y 6 m^c^----S, CYes\<15y\<15y\<17yNoYesNo------98/M--1967PM25y^c^PJS 2 yNoYes11y2y14y25yYesNo------99/F--197216y39y 11 mPJNoNo16y11y28y30y30yYesYes----c.1211G \> A(p.Arg404Gln)/c.1133 T \> C(P.Val378Ala)100/M--197114y29y 2 m^c^No13y 5 m13y13y 5 m13y13y 5 m13yNoYesNo------101/F--196318y40y 3 m^c^PJNoE 31y16y12y16y23y16yYesNo----c.1843C \> T(p.Arg615Cys)/c.2972-2973del(p.Gln991ArgfsX15)102/Fn--Teens23y^c^NoNo--NoTeensTeensTeens23y--No----c.3182 T \> C(p.Ile1061Thr)/?103/M--198720y24y 5 mNoNoNo\<19yNo13y22yNo13yYes22y2yc.2861C \> T(p.Ser954Leu)/c.3107C \> T(p.Thr1036Met)104/M--19726y39y 8 mNoHS 5yNoNoNo6yNoNoNoNo----c.1844G \> T(p.Arg615Leu)/c.1844G \> T(p.Arg615Leu)105/M--1969Early 20s37y 8 m^c^PJS 4yE 30yYes11y20sYesNoYesNo------106^a^/Fo197627y35y 10 mNoNoNo27y13y26y26yNo27yYes----c.1552C \> T(p.Arg518Trp)/c.1552C \> T(p.Arg518Trp)107/Mo197230y37y 2 m^c^NoNoTeens26y26y26y27y25y26yNo----c.1552C \> T(p.Arg518Trp)/c.1552C \> T(p.Arg518Trp)^a^Patients included in previously reported NPC Registry baseline characteristics study \[[@CR19]\]; ^b^Patients included in previously reported NPC Registry baseline and longitudinal data study \[[@CR19], [@CR20]\]; ^c^patient died; ^d^second mutant allele not found after full genome sequencing. '--', no data/not known; *C* cataplexy, *E* epilepsy, *FA* foetal ascites, *Gx* gastrostomy, *HM* hepatomegaly, *HS/S* hepatosplenomegaly/splenomegaly, *LD* liver disease, *LTx* liver transplant, *m* months, *NC* neonatal cholestasis, *PJ* prolonged jaundice, *PM* post mortem, *y* years, *w* weeks

Neurological manifestations were substantially more common than visceral symptoms in this subgroup. Ataxia was the most common neurological manifestation (in 39/42 \[93 %\] patients), followed by VSGP and childhood developmental delay or cognitive problems (both in 38/42 \[91 %\]), dysphagia (35/42 \[83 %\]), dysarthria (33/42 \[79 %\]) and seizures/cataplexy (25/42 \[60 %\]) (Fig. [1](#Fig1){ref-type="fig"}). Unlike younger patient subgroups, psychiatric disturbances were recorded in juvenile-onset patients (8/42 \[19 %\] cases). The age at onset of psychiatric disturbances ranged from 16 to 32 years.

Neonatal jaundice and/or cholestatic liver disease were recorded in 14/42 (33 %) patients, and organomegaly was seen in 18/42 (43 %) patients (Fig. [2](#Fig2){ref-type="fig"}). While no specific neurological signs were recorded in one patient (patient 81), evidence of neurological involvement was documented at the local treatment centre. However, it is not possible to report this patient's presenting neurological manifestation as he was lost to follow up.

### Adolescent/adult-onset patients {#Sec17}

Overall, patients with neurological onset during adolescence or adulthood were characterized by insidious onset and slow disease progression (Table [6](#Tab6){ref-type="table"}). Neurological onset in this older age subgroup occurred at a mean (SD; range) age of 24.2 (8.8; 15.0--40.0) years. The mean (SD) period between neurological onset and diagnosis was 6.0 (6.26) years, and all evaluable patients in this subgroup were diagnosed after the appearance of neurological symptoms. By data cut-off, a total of 8/24 (32 %) patients had died (mean \[SD\] age at death, 33.7 \[6.2\] years). Among patients with available records, seven were recorded as being due to NP-C.Table 6Patients with adolescent-adult neurological onsetPatient number/GenderSibshipDate of birthAge at diagnosisAge at last FU (y, m)/death^c^Neonatal LDHS/SSeizures/cataplexyVSGPDev. delay/cognitive problemsAtaxiaSwallowing problemsPsychiatric disturbanceSlurred speechMiglustat?Age at 1^st^ miglustat startMiglustat durationGenetic mutations108^b^/Mm197623y39yPJNoNo17y17y25y25yNoYesYes32y3yc.3182 T \> C(p.Ile1061Thr)/c.3019C \> G(p.Pro1007Ala)109/F--197518y30y^c^NoNoE 18y 6 m18y15y15y24y18yYesNo----c.3182 T \> C(p.Ile1061Thr)/c.3019C \> G(p.Pro1007Ala)11/M--197820y27y 3 m^c^NoNoNo\<24y\<20yNo23yYes--No------111/F--197525y 6 m30y^c^NoNoC 25y25y16y24y23yNo23yNo------112/Mn197124y40y 2 mNoNoNo16y24y\<24yNo29y32yNo----c.3182 T \> C(p.Ile1061Thr)/?113/Mp196819y43y 2 m^c^NoS 18yE 17y25y18y18y25y17y18yNo----c.1843C \> T(p.Arg615Cys)/c.3289-3291del(p.Asp1097del)114^a^/M--198722y24y 11 mNoNoNo22y15y15y23yNo18yYes24y0.5y--115/Mp196918y28y 8 m^c^NoS 1y 4 mNoYesYesYes25y28yYesNo----c.1843C \> T(p.Arg615Cys)/c.3289-3291del(p.Asp1097del)116/F--196338y48y 6 mNoNoNo\<34y37y34y39yNo34yYes39y^e^--c.1133 T \> C(p.Val378Ala)/c.422_423dup(p.Lys142X)117^a^/Fo197825y33y 11 mNoNoNoNo25y25y32yNo32yYes29y4yc.1552C \> T(p.Arg518Trp)/c.1552C \> T(p.Arg518Trp)118/M----27y35y 4 m--YesTeensNoYesYesYes20sYesNo------119^d^/F--196632y42yNoNoNoYes\<18y29y38yNo38yYes37y8c.3182 T \> C(p.Ile1061Thr)/?120/M--197229y39y 10 m^c^--------Yes--------No------121^a^/M--198220y29y 2 mNoNoNo--Yes------YesNo------122/M--196431y48y 6 mNoYesNoYes46yNoYesNoNoYes42y5y--123^a^/Mq196740y44y 5 m--NoTremor\<40y\<40y\<40yNoNoNoYes43y1yc.1408G \> C(p .Ala 470 Pro/c.1816G \> C (p.Glu608Gln)124/F--196149y50y 11 mNoNoNo46y42y42y49y40y42yYes49y1yc.2000C \> G(p.Ser667Trp)/?125/Fr198129y30y 3 m^c^No20yNo20s20s20s20sTeens20s------c.2764C \> T(p.Gln922X)/c.1133 T \> C(p.Val378Ala)126/Mr198525y26y 8 mNoNoNo25yMild 25yNoNoNoNoYes25y1yc.2764C \> T(p.Gln922X)/c.1133 T \> C(p.Val378Ala)127/M--196942y42y 6 m--NoTremor (20s)\<34y\<34yYes40yNoYesNo43y--c.2903A \> G(p.Asn968Ser)/c.3182 T \> C(p.Ile1061Thr)128/F--195449y 6 m57y 6 mNoNoNoYesYes20sNoNo20sNo----c.3182 T \> C(p.Ile1061Thr)/?129/F----PM40y^c^------------------------c.3182 T \> C(p.Ile1061Thr)/c.2861C \> T(p.Ser954Leu)130/Mq--40y41y 9 m--40yTremor (35y)YesNoYes40yNoNoYes39y--c.1408G \> C(p .Ala 470 Pro/c.1816G \> C (p.Glu608Gln)131/F----27y27y 8 mNoNoNoNoNo25yNo27yNoNo----c.3022A \> C p (Asn 1008 His)/c.3182 T \> C p.(Ile 1061Thr)132^a^/Ms1974Early 30s----------20y--------Yes----c.2336del (p.Phe779SerfsX2)/c.2621A \> T(p.Asp874Val)^a^Patients included in previously reported NPC Registry baseline characteristics study \[[@CR11]\]; ^b^Patients included in previously reported NPC Registry baseline and longitudinal data study \[[@CR11], [@CR12]\]; ^c^patient died; ^d^patient 119 F previously subject of case report by Lachmann et al. \[[@CR10]\]; ^e^treatment interrupted (first treatment start at 39 y, second treatment start at 46 y); '--', no data/not known; *C* cataplexy, *E* epilepsy, *FA* foetal ascites, *HM* hepatomegaly, *HS/S* hepatosplenomegaly/splenomegaly, *LD* liver disease, *LTx* liver transplant, *m* months, *NC* neonatal cholestasis, *PJ* prolonged jaundice, *PM* post mortem, *y* years, *w* weeks

A history of developmental delay and/or cognitive deterioration was the most frequently recorded neurological manifestation (in 21/25 \[84 %\] patients), followed by VSGP and ataxia (both in 18/25 \[72 %\] patients). Dysarthria, dysphagia and seizures/cataplexy were present in 28--64 % of patients. Among those with available information on time of onset of specific manifestations, the majority of neurological signs seemed to appear during adulthood. In particular, patient 124 had no observable neurological symptoms up until her 4^th^ decade of life, during which a full spectrum of characteristic neurological signs as well as psychiatric problems occurred. Patient 129 had a long history of neurological problems but no data on age at onset or recorded details on specific neurological manifestations. Patient 132 displayed cognitive deterioration since his twenties, but again, no information is available regarding specific neurological manifestations.

As in the juvenile-onset subgroup, psychiatric disturbances and/or cognitive deterioration were prominent in the adolescent/adult-onset subgroups, recorded in a total of nine patients (36 %). The age at onset of psychiatric disturbances ranged between 17 and 40 years.

There was only one historical record of neonatal jaundice in this subgroup, and organomegaly was recorded in a total of 6/25 (24 %) patients. Splenomegaly or hepatosplenomegaly were observed in three patients during adulthood (at age 18--40 years; patients 113, 125 and 130), and splenomegaly was recorded during the neonatal period in one patient (patient 115 at age 16 months).

### Patients with no neurological manifestations {#Sec18}

There were a total of 14 patients who had not displayed any neurological manifestations by data cut-off (Table [7](#Tab7){ref-type="table"}). Genetic analyses have revealed *NPC1* mutations in the majority (*n* = 10; 71 %) of these patients, confirming NP-C. Diagnoses among those without identified gene mutations were confirmed based on filipin staining. All of these patients had at least one early visceral symptom of NP-C: neonatal liver disease (mostly prolonged jaundice) and organomegaly both occurred in 11/14 (79 %) patients in this subgroup. Two patients (141 and 143) died in their 2^nd^ and 3^rd^ decades of life due to non NP-C related causes, and patient 146 died aged 4 years due to liver cancer. The remainder of non-neurological patients were alive at data cut-off. The mean (SD) age at last follow up prior to data cut off was 2.5 (1.8) years (range 0.5--6.1 years; *n* = 11). Among the three patients who died, mean age at death was 20.8 (15.9) years (range 4.9--36.7).Table 7Patients with no neurological symptomsPatient number/GenderSibshipDate of birthAge at diagnosisAge at last FU (y, m)/death^a^Neonatal LDHS/SSeizures/cataplexyVSGPDev. delay/cognitive problemsAtaxiaSwallowing problemsPsychiatric disturbanceSlurred speechGenetic mutations133/M--20104 m6 mYesNoNoNoNoNoNoNo----134/M--20108 m8 mYes----------------c.3182 T \> C(p.Ile1061Thr)/?135/M--20101y1yYes (LTx)YesNoNoNoNoNoNoNo--136/M--20066 m2y 5 mPJ LD\<4yNoNoNoNoNoNoNoc.3182 T \> C (p.Ile1061Thr)/c.3182 T \> C (p.Ile1061Thr)137/M--20032y6m6y 1 mNoYesNoNoNoNoNoNoNoc.3182 T \> C (p.Ile1061Thr)/c.3467A \> G (p.Asn1156Ser)138/M--20094 m2y 1 mPJ LDYesNoNoNoNoNoNoNoc.3182 T \> C (p.Ile1061Thr)/?139/Mt2010\<1y1yYesYesNoNoNoNoNoNoNoc.3182 T \> C (p.Ile1061Thr)/c.3289G \> A (p.Asp1097Asn)140/Mt2006--5yNoNoNoNoNoNoNoNoNoc.3182 T \> C (p.Ile1061Thr)/c.3289G \> A (p.Asp1097Asn)141/Fs19711y5m36y 8 m^a^PJ LDBirthNoNoYesNoNoNoNoc.2336del (p.Phe779SerfsX2)/c.2621A \> T (p.Asp874Val)142/F--20082y5m3yYesYesNoNoNoNoNoNoNoc.3182 T \> C (p.Ile1061Thr)/c.3259 T \> C (p.Phe1087Leu)143/M--198716y20y 10 m^a^PJBirthNoNoNoNoNoNoNoc.2621A \> T (p.Asp874Val)/c.3591 + 4 delA144/M--20071y9m4yNoYesNoNoNoNoNoNoNo--145/M--20094 m2yYesYesNoNoNoNoNoNoNo--146/F--20047 m4y 11 m^a^PJYesNoNoNoNoNo--Noc.3083-3084delP.Gly1028AlafsX22)/c.2201G \> T(p.Ser734Ile)^a^Patient died; '--', no data/not known; *HS/S* hepatosplenomegaly/splenomegaly, *LD* liver disease, *LTx* liver transplant, *m* months, *PJ* prolonged jaundice, *y* years, *w* weeks. Note that none of the non-neurological patients had received miglustat by data cut-off end-2011

Genetics {#Sec19}
--------

Overall, 116/146 (79 %) patients had at least one identified NP-C gene mutation (Tables [2](#Tab2){ref-type="table"}--[6](#Tab6){ref-type="table"}**)**. Two mutations were recorded in 78/146 (53 %) patients and one mutation was recorded in 38/146 (26 %) patients. Most patients (98 %) with recorded mutant alleles had *NPC1* mutations, and two patients (2 %) had *NPC2* mutations (one with homozygous c.58G \> T(p.Glu20X) mutant alleles and one with a single identified mutation for which information was not available). Thirty patients (21 %) had no recorded information regarding identified NP-C gene mutations. This number may be reduced in future with the increasing availability of next-generation sequencing methods.

Amongst a total of 194 identified mutant NP-C gene alleles, 53 have been classified as novel mutations. The common I1061Thr mutation was recorded in a total of 55 (38 %) patients in the whole cohort (heterozygous in 89 % and homozygous in 11 % of cases). Among the age-at-neurological onset subgroups, I1061Thr mutant alleles were mainly observed in patients with the late infantile- (23/51 \[45 %\]) and juvenile-onset forms (18/42 \[43 %\]). A lower proportion of patients in the adolescent-adult onset group had this mutation (7/25 \[28 %\]). However, the prevalence of I1061Thr mutations was particularly high among non-neurological patients (*n* = 7 \[50 %\]; six heterozygotes and one homozygote). One patient with a I1061Thr allele (patient 73), also had a c.882-40 T \> A mutant allele, and family studies detected this genotype in the child's father. However, it is not currently known if the c.882-40 T \> A allele is a pathogenic mutation.

Eight patients with available genetic information had the p.Pro1007Ala mutation. Cases were fairly evenly distributed between the late-infantile, juvenile and adolescent/adult-onset subgroups.

Full genome sequencing performed in a number of patients with one identified mutation failed to detect any second mutation. These patients (and their listed genotypes) were: 11 (c.2819C \> T(p.Ser940Leu/?), 18 (c.2008_2011del(p.Cys670ProfsX17/?), 28 (c.3182 T \> C(p.Ile1061 Thr)/?), 31 (c.3182 T \> C(p.Ile1061Thr)/?), 51 (c.3467A \> G(p.Asn1156Ser)/?), 52 (c.3467A \> G(p.Asn1156Ser)/?), 53 (c.3591 + 4delA/?) and 66 (c.1211G \> A(p.Arg404Gln)/?).

Miglustat use {#Sec20}
-------------

The information regarding miglustat use should be regarded in recognition of the year during which miglustat became commercially available in the EU (2009), and of the time of data cut-off. Overall, 51 patients (35 %) received miglustat during the observation period (Tables [2](#Tab2){ref-type="table"}--[6](#Tab6){ref-type="table"}): 2/8 (25 %) early infantile-onset patients and 17/51 (33 %), 20/42 (48 %) and 12/25 (48 %) patients in the late infantile-, juvenile-, and adolescent/adult-onset subgroups, respectively. No patients with the neonatal form of NP-C and no patients in the 'non-neurological' subgroup received miglustat.

The mean ages at treatment start ranged from 0.5 to 49.0 years across the age-at-onset subgroups. Among a total of 38 patients with evaluable information on treatment duration, the overall estimated mean (SD) treatment duration was 2.6 (2.3) years: median (range) 2.0 years (1 week to 8 years). Approximate mean (SD) durations per evaluable age-at-onset subgroup were: 2.6 (2.0) years in late infantile-, 2.8 (2.4) years in the juvenile-, and 2.9 (2.6) years in the adolescent/adult-onset subgroups.

Disease course among related patients {#Sec21}
-------------------------------------

A total of 44 patients from 20 families in this cohort were siblings, most of whom (38 \[86 %\]) had at least one identified *NPC1* mutant allele (see Additional file [1](#MOESM1){ref-type="media"}: Table S1). No NP-C gene mutations were identified in three sibling pairs: diagnoses were established by other means based on clinical symptoms and/or laboratory biochemical (filipin testing) and histological methods.

In general, ages at neurological onset and clinical phenotypes appeared congruent between siblings with identical mutant genotypes. Exceptions included patient 6, the sister of patients 25 and 26, all of whom were homozygous for the c.3020C \> T (p.Pro1007Leu) mutant allele. Patient 6 had the neonatal-onset form of NP-C, neonatal liver disease and hepatosplenomegaly, and died aged 2 months due to failure to thrive and severe chest infection. Her sisters are twins and have late-infantile onset NP-C. Both twins also had neonatal jaundice and hepatosplenomegaly, with a variety of characteristic neurological signs observed from before the age of 4 years, but both were still alive at the time of data cut-off.

Another sibling pair (patients 80 and 108) were both heterozygotes with c.3182 T \> C (p.Ile1061Thr) and c.3019C \> G (p.Pro1007Ala) mutant alleles. The older sibling (patient 108) has adolescent/adult-onset NP-C, presented with VSGP, developmental delay and psychiatric disturbances in his late-teens, and survives aged 39 years at last follow up: he had received miglustat therapy for 3 years at data cut-off. His brother (patient 80) had juvenile-onset NP-C and presented with developmental delay and VSGP before 10 years of age. He also had severe seizures that are considered likely to have contributed to his death 'due to NP-C' at the age of 18 years.

Finally, patients 139 and 140 both have no neurological manifestations. While patient 139 was diagnosed at an early age following investigations of neonatal liver disease and organomegaly, his older brother has no record of systemic manifestations, and was diagnosed (based on genetic testing) due to mainly to his sibling disease history.

Discussion {#Sec22}
==========

It is important to continue gathering knowledge on the natural history of NP-C in order to aid in the clinical management and targeted therapy of affected patients, and to aid in providing counselling and support for their families and caregivers. This summary of data from 146 historical and current UK-based NP-C patients analysed between 1999 and end-2011 provides findings from the largest national NP-C cohort reported to date. Although some patients have minimal data available, they are still included in this report to indicate the full extent of the UK NP-C cohort and provide as full a clinical picture of diagnosed patients as possible.

Based on recent estimates of the total UK population (64.1 million) and national birth rate (12.27/1000) the current birth prevalence of NP-C in the UK is 0.78 cases per 100,000 births, which seems roughly in line with previous estimates of birth prevalence of NP-C in Western Europe (France, Germany and the UK) over the period 1988--2002 \[[@CR21], [@CR22]\]. Based on records of all known UK cases diagnosed since 1985, the rate of diagnoses per decade (i.e., the mean number across all years within each decade) has risen steadily over the last three decades, from 3.5 new cases/year during 1985--1994 to 5.1 new cases per year during 1995--2004, and 6.0 new cases per year during 2005--2011. In addition, a total of 21 new cases have been diagnosed between 2012 and 2015, although these most recent cases are not included in this cohort analysis due to non-availability of access to full clinical information after data cut-off. This trend possibly reflects increased awareness of the disease over the last two decades and, in particular, improvements in genetic analysis methods for confirmation of disease-causing mutations.

Data on visceral symptoms in this cohort were in line with baseline data from 163 patients included in the International NP-C Registry \[[@CR19]\]. Neonatal liver disease and/or prolonged jaundice, or a history of just neonatal jaundice, was a feature in all age subgroups in this cohort. As could be expected, neonatal jaundice was recorded in many patients (50--100 %) in the infantile-onset subgroups, and in far lower proportions of patients (0--33 %) in the juvenile- and adolescent/adult-onset subgroups. There was a clear trend for decreased occurrence of organomegaly with increasing age at neurological onset, although organomegaly was not as common in the neonatal-onset subgroup as it was among early-infantile onset patients due to its incremental nature. Nevertheless, splenomegaly is generally considered a consistent indicator of possible NP-C in neonates, and has often served as a signal leading to early diagnosis.

NP-C has been reported as the second most common genetic cause of liver disease during infancy in the UK, after alpha-1-antitrypsin deficiency \[[@CR23], [@CR24]\], and investigations to exclude NP-C are common practice in liver disease/neonatal units. A large proportion of early-onset patients in this cohort underwent extensive liver investigations during the neonatal period, but in many cases NP-C was subsequently diagnosed years later, after the appearance of neurological signs. This seems typical of the NP-C population as a whole, as reflected by substantial delays to diagnosis in many cases, globally, and reflects the need for clinicians in all specialities to take a full clinical history when seeing new patients.

Based on previous clinical observations, neonatal jaundice without other overt signs of liver disease can herald a more aggressive clinical course of NP-C, particularly if neurological abnormalities appear during the first 4 years of life \[[@CR15], [@CR24]\]. However, the degree of neonatal liver disease does not appear to be a reliable indicator of future disease progression, as illustrated by cases where neurological manifestations became apparent during adulthood despite a history of neonatal liver disease. It is important to consider that early visceral symptoms lack prognostic value in NP-C during family counselling for NP-C cases diagnosed during the neonatal period, providing advice for planning ahead for the emotional and financial burdens of the disease \[[@CR25]\]. Of particular note are the sibling patients 132 and 141, who share identical novel heterozygous *NPC1* mutations. Both had very severe neonatal liver disease necessitating intensive care, and were followed up over a course of years by their hepatologist. Patient 141 had non-neurological NP-C and died at the age of 36 due to a severe infection in late pregnancy: post-mortem examination showed no storage or neurological problems. Her brother (patient 132) was still alive and self-caring at data cut off, and displayed mild cognitive impairment at last follow up.

The profile of neurological manifestations recorded in this cohort was consistent with other large-cohort NP-C studies \[[@CR2], [@CR4], [@CR16], [@CR19], [@CR26]\], with over half of patients displaying one or more of: ataxia; VSGP; dysarthria; dysphagia; and seizures/cataplexy. In terms of age at neurological onset, two-thirds of patients fell into the late infantile-onset and juvenile-onset subgroups. Given the frequency of childhood-onset forms of NP-C in this UK cohort up to the end of 2011, it is not surprising that developmental delay or cognitive deterioration were the most frequently recorded neurological manifestations. Similarly, the frequency of seizures and/or cataplexy was reflective of the overall young age at onset among UK patients, as seizure activity has generally been reported most frequently among patients with late-infantile and juvenile-onset disease \[[@CR1]\].

It is notable that ataxia, which is a central component of the recently developed NP-C suspicion index (SI) for the detection of NP-C among patients with suggestive clinical symptoms \[[@CR9]\], was the second-most common neurological manifestation in this cohort. VSGP is recognised as one of the earliest signs of neurological deterioration in NP-C \[[@CR1], [@CR9], [@CR27], [@CR28]\], so it is unsurprising that this neurological sign was also common. Excluding neonatal cases, VSGP was observed in over half of all UK patients, and was most frequent in those with the juvenile-onset (classical) form of NP-C.

Psychiatric manifestations were only recorded in patients in the juvenile and adolescent/adult-onset subgroups, which is in agreement with previous screening data \[[@CR29]\] and numerous other published findings \[[@CR1], [@CR2], [@CR30]--[@CR34]\]. While little information was available on the precise types of psychiatric disorders for this analysis, patients with juvenile-onset NP-C tend to manifest behavioural problems, impaired learning, and expressive language disorder, which often culminate in failure at school \[[@CR1]\]. Patients with adolescent/adult-onset NP-C and psychiatric disorders often exhibit schizophrenia-like psychosis (in up to 25 % of cases), but can also be diagnosed with bipolar disorder, depression and obsessive-compulsive disorder \[[@CR1], [@CR34]\].

While the severe neonatal and early-infantile onset forms of NP-C resulted in rapid deterioration and early mortality in the current cohort, total mortality decreased with increasing age at neurological onset among the late-infantile (59 %), juvenile (45 %) and adolescent/adult-onset (32 %) subgroups. Mean age at death values reflected this trend. Some adolescent/adult-onset patients have survived into their fifth and sixth decade of life, which confirms the more insidious, mild course of neurological deterioration that has been reported before among adults with NP-C \[[@CR1], [@CR26]\]. Indeed, a recent case has been reported of a 66 year-old female who remains free of any neurological or psychiatric manifestations 18 years after initial presentation \[[@CR35]\].

Wide genetic variability coupled with a high degree of phenotypic heterogeneity make genotype--phenotype correlations difficult in NP-C. Variable clinical phenotypes have even been observed in monozygotic twins with the same genetic mutation \[[@CR36]\]. Overall, 53/194 (27 %) mutations identified in this cohort were classified as novel. The exon 21 (p.I1061Thr) mutant allele of *NPC1* has previously been associated with the common juvenile-onset form of the disease, and is associated with a relatively well characterised cellular function and biochemical phenotype \[[@CR37]--[@CR39]\]. The overall prevalence of this allele has been quoted as approximately 15 % \[[@CR21]\], although more recently it has been reported as particularly frequent (in 20--25 % of diagnosed cases) in France and the UK \[[@CR2]\]. Based on this cohort update, the p.I1061Thr mutant allele was present in 38 % of patients overall, occurring in approximately equal proportions of patients in the late-infantile and juvenile-onset subgroups. The incidence of the second most frequent known *NPC1* mutation -- p.1007Ala -- appeared relatively much lower, occurring in the heterozygous state in only eight patients overall. The prevalence range for p.1007Ala alleles among the late-infantile, juvenile and adolescent/adult-onset subgroups was 4--10 %.

Interestingly, the prevalence of p.I1061Thr mutations was particularly high in the non-neurological subgroup, where it occurred in 50 % of patients. This begs the question of whether some patients currently in the non-neurological group might progress to develop neurological manifestations in the future. For instance, 'non-neurological' patient 136 had no neurological symptoms at last documented follow up aged 2.5 years. However, other patients with homozygous p.I1061Thr mutations (patients 46 and 81--84) all had late-infantile or juvenile onset neurological symptoms. In the same way, many patients with heterozygous p.I1061Thr mutations developed neurological symptoms during the late-infantile period (up to 6 years of age, *n* = 21), the juvenile period (*n* = 14), or during adolescence/adulthood (*n* = 7). Further follow-up might therefore result in re-categorisation of some or all of the 'non-neurological' p.I1061Thr patients as having symptomatic neurological disease. Nevertheless, the same cannot be said for eight patients in the non-neurological group in whom p.I1061Thr mutations have been excluded, and/or in whom no known *NPC1* mutant alleles have been detected.

Substrate reduction therapy (SRT) using miglustat has been shown to be effective in treating adult patients with Gaucher disease \[[@CR40]--[@CR44]\], and subsequently in the treatment of progressive neurological manifestations in children and adults with NP-C \[[@CR1], [@CR28], [@CR45]--[@CR48]\]. In total 34 % of UK patients have received miglustat therapy for any period of time. Longitudinal analyses of serial clinical status assessments are required to determine the impact of miglustat on neurological disease progression in this cohort.

Conclusions {#Sec23}
===========

In summary, the prevalence of NP-C in the UK is in line with previous observational data from other European cohorts, and it is notable that the annual rate of diagnosis of the condition has increased over the past 30 years, possibly due to increasing awareness and improvements in molecular diagnostic methods. The wide phenotypic variability and the overall profile of genotypes detected among UK patients are also consistent with data from other Western populations. In particular, age at onset of neurological manifestations once more appeared associated with more rapid disease progression and a lower age at death. Further analyses are required to assess the impact of miglustat therapy on neurological disease progression.

Additional file {#Sec24}
===============

Additional file 1: Table S1.Comparison of sibling profiles. (DOCX 42 kb)
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NP-C

:   Niemann-Pick disease type C
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